Schoenberg Mark's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Aug 3, 2021
- Accession no.
- 0001209191-21-049477
- Filed
- Aug 3, 2021
- Trade date
- Jul 31-Aug 2, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.80K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schoenberg MarkCIK 0001763581 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 31, 2021 | Ordinary Shares | MOption exerciseAcquired | +500 | –F1 | – | 21,737 | Direct | |
| Aug 2, 2021 | Ordinary Shares | SSaleDisposed | −243 | $15.64 | −$3,800.52 | 21,494 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 31, 2021 | Ordinary Shares | MOption exerciseDisposed | −500 | $0.00 | $0 | 3,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
Referenced by the price of 1 transaction in Table I.